The brokerage expects some slowdown from a high base of 4QFY20.

Buy Cadila Healthcare Ltd. at a price target of Rs 489.0 .

Better than expected sales and net profit growth, limited impact of US FDA due to its limited exposure, and among other things, have made i...

Buy Cadila Healthcare Ltd. at a price target of Rs 444.0 .

Buy Cadila Healthcare Ltd. at a price target of Rs 600. Edelweiss says Cadila's US business growth will be best-in-class at 48 per cent wit...

We should expect significant approval coming in, in FY18 we expect 40 plus approvals may be happening now.

ETMarkets.com surveyed 15 top global brokerages and mutual fund houses, most of which expect a revival either in December or March quarter.

Citigroup sees limited scope for further deterioration in Cadilla Healthcare financials.

The performance has been remarkable on a sequential basis. Net profit more than doubled compared with the previous quarter, largely on acco...

The June quarter results are likely to remain weak given competition in HCQS, lower share in key drugs. Once Moraiya is cleared, Cadila sho...

Morgan Stanley estimates that Cadila can generate up to $35 million upside and could generate over 90 per cent in PBT margins

Brushing aside Brexit fears, China jitters, Rajan’s exit and the possibility of a rate hike by the US Fed, the Nifty50 has risen over 20 pe...

The pricing pressure in the key US product, HCQS has started to show up which will weigh on the stock. HCQS could see further price decline...

Stock-specific movements are going to continue as companies that have delivered good numbers are good to be rewarded, possibly more than wh...

India's fifth largest drug maker by revenue, Zydus Cadila Group has settled a patent litigation with US-based Warner Chilcott Company LLC.

Cadila Healthcare along with Zydus Pharmaceuticals have entered into an agreement with Warner Chilcott Company to settle all outstanding pa...

American consumer products major Procter & Gamble Company will be selling its global pharmaceuticals business to Ireland-based pharma entit...